Johnson & Johnson $JNJ Shares Sold by GWN Securities Inc.

GWN Securities Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 42.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 52,984 shares of the company’s stock after selling 39,486 shares during the period. Johnson & Johnson accounts for approximately 1.5% of GWN Securities Inc.’s portfolio, making the stock its 12th largest position. GWN Securities Inc.’s holdings in Johnson & Johnson were worth $8,151,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $190.31 on Tuesday. The firm has a 50 day moving average of $182.54 and a 200-day moving average of $166.65. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a market cap of $458.50 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is currently 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Finally, Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.